Expression And Diagnostic Value Of LncRNA TUG1 And LncRNA UCA1 In Non-small Cell Lung Cancer Plasma

Background:Lung cancer is the most common cancer in the world,ranking first in morbidity and mortality worldwide.Non-small cell lung cancer is the main histological type of lung cancer,with insidious onset and poor prognosis.Most non-small cell lung cancer(NSCLC)is already in the progressive stage when diagnosed,and early detection provides opportunities for early intervention and treatment,or even radical treatment by early surgery.Therefore,it is necessary to search for potential biomarkers of lung cancer in order to provide early warning for the detection of lung cancer.Long-chain non-coding RNA(lncRNAs),a class of RNA molecules with a length of more than 200 nucleotide(nt)and a lack of protein-coding capacity,were largely ignored by researchers at first.In recent years,lncRNAs have been widely concerned for their involvement in the development of various cancers.LncRNA TUG1,located at site 22q12 of chromosome,was first found to be related to the development of retina and the formation of photoreceptors.Studies have reported that compared with paracancer tissues,lncRNA TUG1 is down-regulated in lung cancer tissues.LncRNA UCA1 is located at chromosome 22p13.12 and was first found in bladder cancer tissues.Studies have shown that lncRNA UCA1 plays a carcinogenic role in most cancers,and it is up-regulated in NSCLC tissues and involved in the occurrence and development of NSCLC.However,at present,there are few studies on the expression levels and diagnostic value of lncRNA TUG1 and lncRNA UCA1 in the plasma of NSCLC patients.This study attempts to explore the potential value of lncRNA TUG1 and lncRNA UCA1 in the diagnosis of NSCLC by detecting the expression levels of lncRNA TUG1 and lncRNA UCA1,so as to provide early warning for the early detection of NSCLC.objective:1.Investigate the expression of lncRNA TUG1 and lncRNA UCA1 in the plasma of NSCLC patients.2.Explore the clinical value of lncRNA TUG1 and lncRNA UCA1 in the diagnosis of NSCLC.3.Explore the relationship between the expression levels of lncRNA TUG1 and lncRNA UCA1 and the clinicopathological characteristics of NSCLC patients.Methods:1.Study subjects: 60 patients with non-small cell lung cancer(NSCLC group)and 60 patients with benign lung disease(benign lung disease group)at the same time were selected as the study objects.All subjects visited the department of respiratory and thoracic surgery in affiliated hospital of jiangsu university from July 2018 to October 2019 to collect peripheral venous blood of the above subjects.2.Reverse transcriptase polymerase chain reaction(qRT-PCR): total plasma RNA was extracted and the relative expression levels of lncRNA TUG1 and lncRNA UCA1 in the plasma of NSCLC patients and patients with benign lung disease were detected by qRT-PCR.Meanwhile,peripheral blood from all the subjects was sent to the department of nuclear medicine,affiliated hospital of jiangsu university to detect the expression levels of CEA and cyfra21-1.3.The ROC curve was constructed to analyze the diagnostic efficacy of plasma lncRNA TUG1 lncRNA UCA1 alone and in combination.4.Clinical data of NSCLC patients were collected and the relationship between plasma lncRNA TUG1 lncRNA UCA1 and clinicopathological characteristics was analyzed by chi-square test.5.Statistical analysis: Statistical software IBM SPSS 22.0,Medcalc(18.2.1)and GraphPad Prism 8.0.1 were used to statistically process and analyze the obtained data.The data of measurement data are expressed by mean plus or minus standard deviation(sx ±),and the comparison is conducted by t test or approximate t test.P<0.05 was considered statistically significant.Results:1.Compared with the benign lung disease group,the plasma lncRNA TUG1 expression in the NSCLC group was down-regulated,while the expression of lncRNA UCA1 was up-regulated,with statistically significant differences(P<0.05).2.The AUC value of plasma lncRNA TUG1 and lncRNA UCA1 in the diagnosis of NSCLC was 0.72(95%CI :0.637-0.815)and 0.69(95%CI :0.602-0.789),and that of CEA and cyfra21-1 in the diagnosis of NSCLC was 0.769(95%CI :0.684-0.855)and0.66(95%CI:0.563-0.757).3.The sensitivity and specificity of serum lncRNA TUG1 in the diagnosis of NSCLC were 81.67% and 50%,respectively.The sensitivity and specificity of lncRNA UCA1 in the diagnosis of NSCLC were 83.33% and 50%,respectively.The sensitivity and specificity of CEA in the diagnosis of NSCLC were 58.33% and 89%,respectively.And the sensitivity and specificity of cyfra21-1 in the diagnosis of NSCLC were 70% and 58.33%,respectively.4.The combined diagnosis of plasma lncRNA TUG1 and lncRNA UCA1 had the highest AUC(0.82%)compared with the diagnosis of NSCLC alone,and the specificity(70%)was improved when the sensitivity was well maintained.There was no correlation between the expression levels of plasma lncRNA TUG1 and lncRNA UCA1 and the gender,age,smoking history,tumor size,pathological classification,TNM stage,lymph node metastasis and distant metastasis of NSCLC patients(P>0.05).Conclusions:The expression levels of lncRNA TUG1 and lncRNA UCA1 in the plasma of NSCLC patients were significantly different from those in the benign lung group.The diagnostic efficacy of the combined detection of two lncRNAs is better than that of their respective detection,which is expected to be a potential diagnostic biomarker for the diagnosis of NSCLC.